HEOR & Market Access

Health Economics, outcomes research and market access

Regulatory entry is secured, now the value story must earn access

Veridian’s health economics and market access practice turns regulatory approval into a reimbursable, payer-ready value story. An HEOR agency builds the dossier, then hands off before negotiation; this practice stays through reimbursement.

Who It's for

Market Entrants

Pharma Affiliates

Global Launch Teams

Payer & HTA Bodies

HTA strategy & payer value proposition

Payer logic, mapped and tested

  • Six-market payer & HTA mapping
  • Payer value proposition and core value-story framework
  • Value message development and testing with payer and clinician panels
  • Comparator, positioning and access-strategy alignment with global HQ

Outcome: A payer-ready value narrative, not a global deck relabeled

Health economic modelling & value dossier

Global evidence, GCC-standard models

  • Cost-effectiveness (CEA) and budget-impact (BIA) modelling to local requirements
  • Value dossier development, adaptation and submission
  • Local data sourcing and evidence-gap resolution where global inputs fall short

Outcome: A submission-ready model and dossier built to withstand scrutiny

Market access diagnostic

The expanded front door

  • What must your asset prove to the relevant authorities?
  • Where does the global model or dossier need local adaptation?
  • What price and access position is realistic under local pricing and budget rules?
  • Recommended access path: pricing sequence, submission timing, evidence gaps to close

Outcome: Four questions answered in one diagnostic

Pricing & payer negotiation

Retained support through listing and renewal

  • Payer negotiation support through submission, appeal and listing
  • Resubmission and renewal cycles tracked against local review timelines
  • Every payer decision surfaced becomes an input to the next negotiation

Outcome: Sustained access, we stay through reimbursement, not just launch

Your value story must earn access

Bring us a GCC pricing, HTA or reimbursement challenge. We will show where your global model and dossier need local adaptation, what price and access position is realistic, and which evidence gaps to close before you submit.
Book Your Diagnostic

Get GCC Access Insights

Practical thinking on registration, HTA, pricing and clinical adoption across the GCC, plus details of upcoming Veridian events.

Ajaz Rashid

Medical affairs & scientific communications

Over 30 years in medical affairs, scientific communications and clinical research in global, regional and local roles. Successful track record in leading people and teams to develop and deliver scientific narratives, programmes and content with demonstrable HCP impact across multiple therapeutic areas including respiratory, immunology, oncology, CV, metabolic, neurology and hepatology.

Dr. Rashmi Hegde

Medical affairs

30 years delivering 80+ Life Sciences product & vaccine regulatory approvals for launches across therapies and geographies. Expertise in Pharmacovigilance, Medical, Clinical, patient affairs, and medical governance. Optimized MA & MSL capabilities, focusing on executional excellence. Achieved 100% PV compliance across 33 global affiliates

Dr. Laura Jotimliansky

Medical affairs & clinical research

30+ years in pharma across multiple TAs and geographies. Internal Medicine and Clinical Pharmacology training with deep LATAM and Middle East focus. At GSK, led regional teams and built Oncology structure across Emerging Markets. Previously at BMS and Roche.

Dr. Elif Coskuncay

Medical affairs

25+ years spanning pharma, clinical practice, and strategic medical affairs at global, regional, and local levels. Therapeutic expertise in oncology, cardiovascular, metabolic, respiratory, rare diseases, and vaccines. Successfully launched life-saving therapies including immuno-oncology in emerging and developed markets.

Rafa Al Khalifa

Market access & stakeholder engagement

Healthcare strategy consultant specializing in specialty pharmacy, market access, patient support programs, health economics, quality, and compliance. UAE MOHAP-registered pharmacist. Led the first ACHC-accredited specialty pharmacy outside the US. FIP SAPS Executive Committee member; represented FIP at the World Health Assembly and COP29. Co-Founder of EcoRx UAE.

Dr. Claudia Soares

Rwe, heor & business intelligence

Physician with MSc/PhD in Epidemiology & Biostatistics and a Master’s in Business Intelligence (focused on AI in healthcare). Over 18 years of experience across academia, government, and the pharmaceutical industry in R&D, Health Outcomes, and Medical Affairs. Led global, regional, and local projects in clinical development, launch planning, epidemiology, health outcomes, real-world data (RWD), and evidence generation, with a strong track record of impact in emerging markets.

Dr. Ali AlHammad

Heor & market access

HEOR expert with strong background in market access, patient-reported outcomes, and medical research. Proven track record developing strategic brand plans for successful launches in Saudi Arabia. Deep understanding of the Saudi healthcare system, translating complex economic data into actionable insights for payers.

Safinaz Issa

Regulatory affairs & market access

Senior Regulatory, Government Affairs & Market Access Executive with 25+ years of leadership across Pfizer, GSK, Sanofi Genzyme, Novartis, Eisai, and Eli Lilly. Led 1,000+ filings and market access strategies across 40+ markets in MEA, Europe, and North America. Expertise spans regulatory strategy and intelligence, health authority engagement, compliance, lifecycle management, and complex product launches across rare diseases, neuroscience, oncology, and medical devices.

Dr. Razia Hussain

Director, Medical Affairs

Senior Medical Affairs and Clinical Research leader with 25+ years of international pharmaceutical experience across Oncology, Immunology, Cardiovascular, Respiratory, HIV, Hepatology, and Specialty Medicine. Led Medical Affairs teams in China and clinical research operations globally, delivering registration studies, evidence generation, pre-launch readiness, and RWE programmes. Developed medical excellence capabilities adopted as global best practices, led a major cardiovascular RWE study in the Middle East, and established a regional pharmacovigilance hub for Africa. Strong track record in medical strategy, cross-functional leadership, stakeholder engagement, and building high-performing teams.

Fayaz Aziz

Managing Director, HTA/HEOR and Market Access

Senior health economics, market access, and medical affairs leader with 25+ years of international experience spanning industry, government, academia, and consultancy across R&D, EU, Emerging Markets, and the Middle East. Led HEOR strategy and medical excellence across 30+ markets at GSK, delivered HTA submissions to NICE and SMC at Pfizer UK, and founded a global HEOR Academy that trained 2,000+ professionals. 15+ years in the GCC, with early career foundations as a public health scientist at the England Department of Health, health policy training at LSE, and doctoral research at LSHTM on AI governance in HTA decision-making.